XML 57 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Additions and Returns of Product Rights - Narrative (Details) - USD ($)
shares in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 24 Months Ended
Apr. 30, 2019
Nov. 30, 2018
Nov. 30, 2016
Jun. 30, 2020
Jun. 30, 2020
Jun. 30, 2019
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]                  
Payment to acquire business upon closing         $ 0 $ 5,000,000      
Clinigen                  
Business Acquisition [Line Items]                  
Revenue           5,300,000      
Direct expenses           3,400,000      
Discontinued operations income         1,500,000 $ 1,900,000      
Inventory                 $ 500,000
Clinigen | Scenario, Forecast                  
Business Acquisition [Line Items]                  
Financial consideration received in exchange for product license rights             $ 5,000,000    
Nordic                  
Business Acquisition [Line Items]                  
Revenue       $ 500,000          
Vibativ                  
Business Acquisition [Line Items]                  
Payment to acquire business upon closing   $ 20,000,000.0     20,000,000        
Cash payment during 2019 $ 5,000,000.0       5,000,000        
Percentage of tiered royalty payments (up to)   20.00%              
Additional liability       8,300,562 8,300,562       $ 8,633,589
Vibativ | Other current liabilities                  
Business Acquisition [Line Items]                  
Additional liability       2,800,000 2,800,000        
Vibativ | Other long-term liabilities                  
Business Acquisition [Line Items]                  
Additional liability       $ 5,500,000 5,500,000        
Methotrexate                  
Business Acquisition [Line Items]                  
Payment to acquire business upon closing     $ 100,000            
Liability recorded     $ 900,000            
Vested common stock, value         $ 900,000        
Methotrexate | Subsequent Event                  
Business Acquisition [Line Items]                  
Additional liability               $ 1,000,000.0  
Methotrexate | Restricted Stock                  
Business Acquisition [Line Items]                  
Unvested restricted shares (in shares)     180